

HETEROCYCLES, Vol. 84, No. 1, 2012, pp. 669 - 682. ©2012 The Japan Institute of Heterocyclic Chemistry
Received, 21st June, 2011, Accepted, 4th August, 2011, Published online, 15th August, 2011
DOI: 10.3987/COM-11-S(P)43

RAPID ONE-POT VERSATILE PREPARATION OF 2-AMINO-BENZO-THIAZOLES BY HIGHLY EFFICIENT COPPER(I)-CATALYZED INORGANIC BASE-FREE INTRAMOLECULAR CYCLIZATION¹

Haruki Sashida* and Mamoru Kaname

Faculty of Pharmaceutical Sciences, Hokuriku University, Kanagawa-machi, Kanazawa 920-1181, Japan


E-mail: h-sashida@hokuriku-u.ac.jp

Abstract – The convenient and versatile one-pot preparation of the 2-aminobenzothiazoles by the highly efficient copper(I)-catalyzed intramolecular cyclization of commercially available *o*-halophenyl isothiocyanates with *N*-nucleophiles has been accomplished. The reaction of not only the *o*-iodophenyl or *o*-bromophenyl isothiocyanates, but also the *o*-chlorophenyl one proceeded under inorganic base-free conditions.

INTRODUCTION

Various methods for the constructions of benzothiazole moieties² are available because of their broad range of biological activities.³ A common approach for the synthesis of the 2-substituted benzothiazole involves the treatment of 2-aminothiophenol with acylating agents, aldehydes or benzyl halides (eq. 1).⁴ The copper catalyzed reaction of aromatic disulfide amines and aldehydes proceeds to give the benzothiazoles *via* the S-S bond fission (eq. 2).⁵ 2-Aminobenzothiazoles are most often prepared by the coupling reaction of 2-haloanilines and isothiocyanates or cyclization of *N*-(2-halophenyl)thioureas, which are obtained by the reaction of 2-halophenyl isothiocyanates with amines or the acylation of 2-haloanilines, followed by treatment with Lawesson's reagent. (eq. 3).⁶ The intramolecular cyclization of the *N*-(2-halophenyl)benzothioamides generally are efficient only for the synthesis of 2-phenyl-1,3-benzothiazoles (eq. 4).⁷ The syntheses of both the O- and S-substituted benzothiazoles were also achieved by the copper(I)-catalyzed reaction of 2-halophenyl isothiocyanates with O- or S-nucleophiles. (eq. 5)⁸ The copper-catalyzed thiolation reaction of *N*-(2-haloaryl)trifluoromethylacetimidoyl chlorides with sulfides has been developed for synthesizing 2-trifluoromethylbenzothiazoles (eq.

Dedicated to Professor Dr. Albert Padwa, Emory University, on his 75th birthday



Scheme 1. Syntheses of 2-substituted 1,3-benzothiazoles

6).⁹ Moreover, the 2-trifluoromethylbenzothiazoles have been synthesized *via* the C-H bond functionalization from trifluoroimidoyl chlorides and NaSH (eq. 7)¹⁰ In addition, the intramolecular cyclization of the unsubstituted thiobenzamides to the benzothiazoles *via* aryl radical cations by the phenyliodine(III) bis(trifluoroacetate) or thiyl radical using hypervalent iodine reagent has been developed (eq. 8).¹¹

The majority of these methods include a transition metal-catalyst such as Pd or Cu, inorganic base and often a ligand. Moreover, the reactions frequently require heated conditions and very limited types of the 2-substituents on the benzothiazole ring.


RESULTS AND DISCUSSION

To overcome these drawbacks, we now describe a highly efficient method for the synthesis of the 1,3-benzothiazoles having an amino group such as NRR' and NHR at the 2-position by the copper-catalyzed inorganic base-free one-pot tandem addition-cyclization reaction of 2-halophenyl thiocyanates (**1**) with *N*-nucleophiles without the isolation of the intermediates, thioureas, in our continuing studies on chalcogen-containing heterocycles.^{12,13}

The treatment of 2-iodophenyl isothiocyanate (**1A**, 1.0 mmol) with piperidine (**2a**, 2.5 mmol) in the presence of CuI (10 mol %) in benzene at room temperature resulted in the direct ring-closure to give 2-piperidino-1,3-benzothiazole (**3a**) in 100% isolated yield; the reaction took place very rapidly and was completed within a few minutes under an air atmosphere (Table 1, entry 1). When 5 and 1 mol % of CuI were allowed to react with the isothiocyanate (**1A**) and piperidine (**2a**) under the same conditions, the 1,3-benzothiazole (**3a**) was formed in 98 and 99% isolated yields, respectively (entries 2 and 3). However,

3a was only slightly formed in the absence of CuI (entry 4), in addition, the use of a 1.0 equivalent of piperidine did not give the desired cyclized product irrespective of the amount of the catalyst; only the thiourea **4Aa** was obtained in 94% yield (entry 5). Both the monovalent (e.g., CuBr and CuCl) and bivalent copper-catalyst (e.g., CuBr₂, Cu(OTf)₂, CuSO₄ and Cu(OH)₂) were almost equally effective; the reaction occurs under copper catalytic conditions (entries 6-11). Fortunately, this tandem addition-cyclization reaction of both the 2-bromophenyl (**1B**) and 2-chlorophenyl isothiocyanates (**1C**) also took place under inorganic base-free similar mild conditions at room temperature to produce the benzothiazole (**3a**), although the reaction time had to be increased for completion; **1B** and **1C** are quite superior to **1A** regarding cost of the substrates (entries 12-17). **3a** was obtained using 10 mol % CuI

Table 1. Reaction of 2-halophenyl isothiocyanates (**1**) with piperidine (**2a**)^a



Entry	Isothiocyanate (X)	Catalyst (mol %)	temp	Time	Yield (%)
1	1A (I)	CuI (10)	rt	2 min	100 ^b
2	1A	CuI (5)	rt	2 min	98 ^b
3	1A	CuI (1)	rt	5 min	99^b
4	1A	None	rt	24 h	trace ^c
5	1A	CuI (1)	rt	24 h	trace ^d
6	1A	Cu Br (1)	rt	10 min	quant ^c
7	1A	CuCl (1)	rt	10 min	quant ^c
8	1A	CuBr ₂ (1)	rt	30 min	quant ^c
9	1A	Cu(OTf) ₂ (1)	rt	20 min	quant ^c
10	1A	CuSO ₄ (1)	rt	4 h	quant ^c
11	1A	Cu(OH) ₂ (1)	rt	20 h	quant ^c
12	1B (Br)	CuI (1)	rt	72 h	72 ^b
13	1B	CuI (10)	rt	24 h	quant ^c
14	1B	CuI (5)	reflux	15 h	quant ^c
15	1C (Cl)	CuI (1)	rt	72 h	70 ^b
16	1C	CuI (10)	rt	24 h	quant ^c
17	1C	CuI (5)	reflux	20 h	quant ^c
18	1A	PdCl ₂ (PPh ₃) ₂ (10)	rt	24 h	trace


^a Standard reaction conditions: isothiocyanate (**1**, 1.0 mmol), piperidine (2.5 mmol), benzene (2.5 mL).

^b Isolated yield.

^c HPLC yield.

^d 1.0 mmol of piperidine was used.


within 24 h from **1B** and **1C** in quantitative yields, respectively (entries 13 and 16). The heating of the isothiocyanates (**1B**, **1C**) with piperidine (**2a**) under 5 mol % CuI conditions in refluxing benzene for 15-20 h afforded the benzothiazole (**3a**) in excellent yields (entries 14 and 17). The use of benzene as a solvent afforded the best results. The thiazole **3a** was obtained in trace by the addition of a palladium catalyst (entry 18).



Scheme 2

Previously reported methods⁸ for the syntheses of the benzothiazoles from the 2-halophenyl isothiocyanates and nucleophiles require a metal-catalyst, an inorganic base such as Na₂CO₃, NaOH, K₂CO₃, KO*t*-Bu, K₃PO₄, and Cs₂CO₃, various ligands, and often higher reaction temperature (eq. 5, Scheme 1). However, in our present investigation, the reaction smoothly proceeded to give the expected benzothiazoles without any inorganic bases, ligands at room temperature, and even *o*-chlorophenyl isothiocyanate. Thus, in order to clarify the details of this difference in the reported methods including the mechanism, we tried to develop more experimentation (Scheme 2). When the treatment of the thiourea **4Aa**, which was easily obtained by the reaction of the isothiocyanate (**1A**) and 1.0 equivalent amount of piperidine (**2a**) in benzene at room temperature, with CuI (5 mol %) as the catalyst in benzene, the reaction did not take place at all. However, the reaction very rapidly proceeded and finished within a few minutes by the addition of piperidine (**2a**) at room temperature. With the addition of piperidine in the absence of CuI, the thiazole **3a** was not obtained from the thiourea **4Aa**. Similarly, when diethylamine or triethylamine as an aliphatic amine was employed, the corresponding product **3a** was almost quantitatively obtained; the use of triethylamine required a long reaction time (e.g., 20-24 h). In these cases, using inorganic bases and ligands are not essential. This fact evidently indicates that the secondary amine operated as a nucleophile toward the isothiocyanate moiety at the first addition step, and had an effect as a base to remove HX on the second elimination step.

Next, the extension of this tandem addition-cyclization of 2-halophenyl isothiocyanates (**1**) with several amine nucleophiles (**2**) was carried out and the obtained results are summarized in Table 2. The present cyclization of the 2-halophenyl isothiocyanates (**1**) with aliphatic, aromatic, secondary and primary mono and diamines almost quantitatively proceeded except for *o*-phenylenediamine (**2n**). 2-Piperidinobenzothiazole (**3a**) was quantitatively obtained from not only *o*-iodophenyl, but also from the *o*-bromophenyl

Table 2. Preparation of 2-amino-1,3-benzotiazoles (**3**)

Entry	Isothiocyanate (X)	Method	Amine	Time	Product	Yield (%) ^a
1	1A (I)	I		5 min		100
2	1B (Br)	III		24 h		100
3	1C (Cl)	IV	2a	20 h	3a	100
4	1A	II	2b	5 min	3b	95
5	1A	II	2c	5 min	3c	97
6	1A	II		5 min		100
7	1B	IV	2d	1 h	3d	96
8	1C	IV		24 h		0 ^b
9	1A	II	2e	20 h	3e	100
10	1A	II	2f	20 h	3f	93
11	1A	V	2g	20 h	3g	98
12	1A	V	2h	24 h	3h	90
13	1A	V	2i	24 h	3i	93
14	1A	VI	2j	24 h	3j	92
15	1A	VI	2k	24 h	3k	81
16	1A	VI	2l	24 h	3l	82
17	1A	VI	2m	48 h	3m	78

Method I: isothiocyanate **1** (1 mmol), amine **2** (2.5 mmol), CuI (0.01 mmol), benzene (2.5 mL), rt.

Method II: isothiocyanate **1** (1 mmol), amine **2** (2.5 mmol), CuI (0.05 mmol), benzene (2.5 mL), rt.

Method III: isothiocyanate **1** (1 mmol), amine **2** (2.5 mmol), CuI (0.1 mmol), benzene (2.5 mL), rt.


Method IV: isothiocyanate **1** (1 mmol), amine **2** (2.5 mmol), CuI (0.05 mmol), benzene (2.5 mL), reflux.

Method V: isothiocyanate **1** (1 mmol), amine **2** (1 mmol), NEt₃ (10 mmol), CuI (0.05 mmol), benzene (2.5 mL), reflux.

Method VI: isothiocyanate **1** (1 mmol), amine **2** (0.5 mmol), NEt₃ (10 mmol), CuI (0.05 mmol), benzene (2.5 mL), reflux.

^a Isolated yield. ^b Thiourea **4Ca** was obtained.

(**1B**) and *o*-chlorophenyl isothiocyanates (**1C**) (entries 1-3, also Table 1, entries 13, 17). *o*-Iodophenyl isothiocyanate (**1A**) similarly reacted with 2.5 equivalents of the secondary amine, pyrrolidine (**2b**) and morpholine (**2c**) in the presence of CuI (5 mol %) in benzene at room temperature to produce the corresponding 2-aminobenzothiazoles (**3b** and **3c**) in 95 and 97% yields, respectively (entries 4, 5). 2-(Diethylamino)benzothiazole (**3d**) was also produced by the reaction of 2-iodophenyl (**1A**) and 2-bromophenyl isothiocyanate (**1B**) with diethylamine (**2d**) in excellent yields (entries 6, 7). Unfortunately, **3d** was not produced from 2-chlorophenyl isothiocyanate (**1C**) and diethylamine (**2d**); only a complex mixture involving the thiourea **4Ca** was obtained. When *n*-butyl (**2e**) and *t*-butyl amines (**2f**) as a primary aliphatic amine were allowed to react with **1A** under similar conditions, the corresponding 2-aminobenzothiazoles (**3e** and **3f**) were also obtained in 100 and 93% yields, respectively, although a prolonged reaction time was needed (entries 9, 10). Aromatic amines, aniline (**2g**), *N*-methylaniline (**2h**) and imidazole (**2i**) also afforded the corresponding products (**3g**, **3h**, **3i**) in good yields (entries 11-13). It is also notable that even when a diamine, such as piperazine and propylenediamine, were employed, the symmetrical products **3j** and **3k** were obtained in 92 and 81% yields, respectively (entries 14, 15). The reaction of three kinds of structural isomers of the phenylenediamine with isothiocyanate **1A** was examined. *m*-Phenylenediamine (**2l**) and *p*-phenylenediamine (**2m**) reacted with **1A** to give the normal 1:2 adducts **3l** and **3m** in good yields as the sole products (entries 16, 17). On the contrary, *o*-phenylenediamine (**2n**) afforded the 1:1 cyclization product **5** (17% yield) and the imidazole derivative **6** (13% yield) in addition to the normal expected 1:2 adducts, the bis(benzothiazoyl) derivaive (**3n**) (13% yield) as shown in Scheme 3. The mono-benzothiazole (**5**) was produced by the copper-catalyzed ring-closure of the monothiourea (**4An**). The formation of the imidazole (**6**) may be explained as follows: the intramolecular nucleophilic attack of the benzothiazol-2-yl-amino moiety on the thiocarbonyl carbon in the mono ring-closure intermediate **8**



Scheme 3

generated the sulfanylimidazole intermediate (**9**), followed by dehydrosulfidation to give **6**. The mechanism for the formation of **6** through **8** and **9** is essentially similar to that of the 2-aminobenzimidazoles from the isoselenocyanates reported by Xie and co-workers.¹⁴

CONCLUSION

In summary, we have developed a simple and practical protocol for synthesizing the benzothiazole moieties having various amino groups at the C-2 position by the copper-catalyzed tandem addition-cyclization reaction of 2-halophenyl isothiocyanates with *N*-nucleophiles in a one-pot reaction. Most importantly, by comparing the reported methodology, this protocol allows the C-S bond formation under inorganic base-free conditions, the products are obtained in high yields, and all the starting materials, e.g., the 2-halophenyl isothiocyanates and amines, are commercially available.

EXPERIMENTAL

Melting points were measured on a Yanagimoto micro melting point hot stage apparatus and are uncorrected. IR spectra were determined with a Horiba FT-720 spectrometer. Mass spectra (MS) and HRMS were recorded on a JEOL JMS-DX300 instrument. NMR spectra were determined with a JEOL JNM-GSX 500 (500 MHz) spectrometer in CDCl₃ or DMSO-*d*₆ using tetramethylsilane as internal standard and *J* values are given in Hz. Microanalyses were performed in the Microanalytical Laboratory in this Faculty.

2-Bromophenyl isothiocyanate, 2-chlorophenyl isothiocyanate, 2-iodophenyl isothiocyanate and all amines are commercially available.

Method I: To a stirred mixture of 2-iodophenyl isothiocyanate (**1A**, 261 mg, 1 mmol) and an appropriate amine (**2**, 2.5 mmol) in benzene (2.5 mL) at room temperature was added CuI (0.01 mmol) at room temperature. The mixture was stirred at same conditions until disappearance of the starting material by the TLC check and evaporated *in vacuo*. The obtained residue was purified by silica gel chromatography using CHCl₃-MeOH (100:3) as eluent to give pure 2-aminobenzothiazole (**3**).

Method II: The 2-halophenyl isothiocyanate (**1**) was treated with CuI (0.05 mmol) and worked up as described for the method I.

Method III: The 2-halophenyl isothiocyanate (**1**) was treated with CuI (0.1 mmol) and worked up as described for the method I.

Method IV: To a stirred mixture of 2-iodophenyl isothiocyanate (**1A**, 261 mg, 1 mmol) and an appropriate amine (**2**, 2.5 mmol) in benzene (2.5 mL) at room temperature was added CuI (0.05 mmol). The mixture was refluxed until disappearance of the starting material and evaporated *in vacuo*. The obtained residue was purified by silica gel chromatography using CHCl₃-MeOH (100:3) as eluent to give

pure 2-aminobenzothiazole (**3**).

Method V: To a stirred mixture of 2-iodophenyl isothiocyanate (**1A**, 261 mg, 1 mmol), an appropriate amine (**2**, 1.0 mmol) and Et₃N (10 mmol) in benzene (2.5 mL) was added CuI (0.05 mmol). The mixture was refluxed until disappearance of the starting material and evaporated *in vacuo*. The obtained residue was purified by silica gel chromatography using CHCl₃-MeOH (100:3) as eluent to give pure 2-aminobenzothiazole (**3**).

Method VI: The 2-halophenyl isothiocyanate (**1**) was treated with the amine (**2**, 0.5 mmol) and worked up as described for the method V.

The benzothiazoles (**3a-i**) were identical with the authentic samples; the melting points and the spectral data of the products were in good agreement with those already reported data except for **3d**, **3e**, **3f**, **3h** and **3i**, and the melting point of **3i** is not described in the literature.^{7g} Thus, the ¹H and ¹³C NMR data of them are reported here.

2-(Piperin-1-yl)benzo[*d*]thiazole (**3a**)

Colorless needles, mp 95.5-96.5 °C (from CHCl₃-hexane), lit.¹⁵ mp 93-94 °C.

2-(Pyrrolin-1-yl)benzo[*d*]thiazole (**3b**)

Colorless prisms, mp 102-103 °C (from CHCl₃-hexane), lit.^{7f} mp 101 °C.

2-(Morpholin-yl)benzo[*d*]thiazole (**3c**)

Colorless plates, mp 118-119.5 °C (from AcOEt-hexane), lit.¹⁶ mp 119-120 °C.

2-(Diethylamino)benzo[*d*]thiazole (**3d**)

Pale yellow oil, lit.^{7f} ¹H NMR (500 MHz, CDCl₃) δ = 1.27 (6H, t, *J* = 7.2 Hz), 3.56 (4H, q, *J* = 7.2 Hz), 7.02 (1H, ddd, *J* = 7.9, 7.4, 1.1 Hz), 7.26 (1H, ddd, *J* = 8.1, 7.4, 1.3 Hz), 7.53 (1H, dd, *J* = 8.1, 1.1 Hz), 7.56 (1H, dd, *J* = 7.9, 1.3 Hz). ¹³C NMR (125 MHz, CDCl₃) δ = 12.9 (q), 45.4 (t), 118.5 (d), 120.5 (d), 120.7 (d), 125.8 (d), 130.6 (s), 153.3 (s), 167.3 (s).

2-(*n*-Butylamino)benzo[*d*]thiazole (**3e**)

Colorless prisms, mp 85-86 °C (from CHCl₃-hexane), lit.¹⁷ mp 68 °C. ¹H NMR (500 MHz, CDCl₃) δ = 0.94 (3H, t, *J* = 7.4 Hz), 1.38-1.47 (2H, m), 1.62-1.70 (2H, m), 3.39 (2H, t, *J* = 7.2 Hz), 6.21-6.36 (1H, br, NH), 7.06 (1H, ddd, *J* = 7.9, 7.3, 1.1 Hz), 7.28 (1H, ddd, *J* = 8.1, 7.3, 1.2 Hz), 7.50 (1H, dd, *J* = 8.1, 1.1 Hz), 7.58 (1H, dd, *J* = 7.9, 1.2 Hz). ¹³C NMR (125 MHz, CDCl₃) δ = 13.7 (q), 20.0 (t), 31.6 (t), 45.5 (t),

118.5 (d), 120.8 (d), 121.2 (d), 125.9 (d), 130.2 (s), 152.5 (s), 168.1 (s).

2-(*tert*-Butylamino)benzo[*d*]thiazole (3f)

Colorless needles, mp 96-96.5 °C (from CHCl₃-hexane), lit.¹⁸ mp 91-95 °C (from EtOAc-hexane). ¹H NMR (500 MHz, CDCl₃) δ = 1.48 (9H, s), 5.20-5.32 (1H, br, NH), 7.06 (1H, ddd, *J* = 7.9, 7.3, 1.2 Hz), 7.27 (1H, ddd, *J* = 8.1, 7.3, 1.3 Hz), 7.54 (1H, dd, *J* = 8.1, 1.2 Hz), 7.56 (1H, dd, *J* = 7.9, 1.3 Hz). ¹³C NMR (125 MHz, CDCl₃) δ = 29.1 (q), 53.3 (s), 119.0 (d), 120.4 (d), 121.4 (d), 125.7 (d), 130.8 (s), 152.4 (s), 164.6 (s).

2-Anilinobenzo[*d*]thiazole (3g)

Colorless needles, mp 163-165 °C (from CHCl₃-hexane), lit.¹⁹ mp 159-160 °C.

2-(*N*-Methylanilino)benzo[*d*]thiazole (3h)

Colorless prisms, mp 76-78 °C (from hexane), lit.²⁰ oil. ¹H NMR (500 MHz, CDCl₃) δ = 3.62 (3H, s), 7.05, 7.38-7.50, 7.62 (1H, ddd, *J* = 7.7, 7.1, 0.9 Hz, 2H, m, 5H, m, 1H, dd, *J* = 8.1, 0.5 Hz). ¹³C NMR (125 MHz, CDCl₃) δ = 40.4 (q), 119.2 (d), 120.4 (d), 121.7 (d), 125.8 (d), 126.0 (s), 127.4 (d), 129.9 (d), 131.2 (s), 145.8 (s), 152.6 (s), 168.2 (s).

2-(Imidazol-1-yl)benzo[*d*]thiazole (3i)

Colorless prisms, mp 135-138 °C (from CHCl₃-hexane), lit.^{7g} ¹H NMR (500 MHz, CDCl₃) δ = 7.22 (1H, s), 7.39 (1H, ddd, *J* = 8.0, 7.4, 1.1 Hz), 7.50 (1H, ddd, *J* = 8.2, 7.4, 1.2 Hz), 7.61 (1H, s), 7.81 (1H, dd, *J* = 8.0, 1.2 Hz), 7.92 (1H, dd, *J* = 8.2, 1.1 Hz), 8.29 (1H, s). ¹³C NMR (125 MHz, CDCl₃) δ = 117.8 (d), 121.6 (d), 122.8 (d), 125.5 (d), 127.1 (d), 131.2 (d), 132.1 (s), 135.9 (d), 150.5 (s), 155.8 (s).

1,4-Bis (benzo[*d*]thiazol-2-yl)piperazine (3j)

Colorless prisms, mp 292-293 °C (from CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ = 3.82 (8H, s, CH₂ x 4), 7.12, 7.33, 7.59, 7.63 (2H, ddd, *J* = 7.8, 7.3, 1.2 Hz, 2H, ddd, *J* = 8.1, 7.3, 1.3 Hz, 2H, dd, *J* = 8.1, 1.2 Hz, 2H, dd, 7.8, 1.3 Hz). ¹³C NMR (125 MHz, CDCl₃) δ = 47.8 (t), 119.5 (d), 120.8 (d), 121.9 (d), 126.2 (d), 130.8 (s), 152.5 (s), 168.4 (s). MS (FAB): *m/z* (relative intensity, %) 353 (7, MH⁺), 134 (57), 119 (64), 84 (93), 39 (100). HRMS (FAB) *m/z* MH⁺ calcd for C₁₈H₁₇N₄S₂: 353.0895, found: 353.0899.

N,N'-Bis(benzo[*d*]thiazol-2-yl)1,3-diaminopropane (3k)

Colorless prisms, mp 193-198 °C (from CHCl₃-hexane). IR (KBr, tab.): 3437 (NH) cm⁻¹. ¹H NMR (500

MHz, CDCl₃) δ = 1.90-2.15 (2H, m, CH₂CH₂CH₂), 3.44-3.53 (4H, m, CH₂CH₂CH₂), 7.02 (2H, dd, J = 7.8, 7.5 Hz), 7.22 (2H, ddd, J = 7.9, 7.5, 1.0 Hz), 7.40 (2H, d, J = 7.9 Hz), 7.66 (2H, dd, J = 7.8, 1.0 Hz), 8.10 (2H, t, J = 5.2 Hz, NH). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 28.3 (t), 41.6 (t), 117.9 (d), 120.75 (d), 120.79 (d), 125.4 (d), 130.2 (s), 152.5 (s), 166.0 (s). MS (EI): m/z (relative intensity, %) 340 (47, M⁺), 190 (37), 177 (100), 150 (34), 136 (40). HRMS (EI) m/z M⁺ calcd for C₁₇H₁₆N₄S₂: 340.0816, found: 340.0819.

***N,N'*-Bis(benzo[*d*]thiazol-2-yl)-*m*-phenylenediamine (3l)**

A mixture of isothiocyanate (**1A**, 261 mg, 1 mmol), *m*-phenylenediamine (**2l**, 54 mg, 0.5 mmol), Et₃N (0.14 mL, 10 mmol) and CuI (10 mg) in benzene (2.5 mL) was refluxed for 48 h. The obtained precipitate was filtered off and washed with H₂O and CHCl₃.

Colorless powder, mp 263-265 °C (from DMF-H₂O). IR (KBr, tab.): 3430 (NH) cm⁻¹. ¹H NMR (500 MHz, DMSO-*d*₆) δ = 7.18 (2H, ddd, J = 7.8, 7.1, 1.1 Hz), 7.30-7.41 (3H, m), 7.50 (2H, dd, J = 8.1, 1.9 Hz), 7.63 (2H, dd, J = 7.9, 7.9 Hz), 7.83 (2H, dd, J = 7.8, 7.8 Hz), 8.25 (1H, s), 10.57 (2H, s, NH x 2). ¹³C NMR (125 MHz, DMSO-*d*₆) δ = 107.1 (d), 111.8 (d), 119.0 (d), 121.0 (d), 122.2 (d), 125.8 (d), 129.4 (d), 130.0 (s), 141.0 (s), 152.0 (s), 161.5 (s). MS (EI): m/z (relative intensity, %) 374 (100, M⁺), 282 (7), 224 (15). HRMS (EI) m/z M⁺ calcd for C₂₀H₁₄N₄S₂: 374.0660, found: 374.0659.

***N,N'*-Bis(benzo[*d*]thiazol-2-yl)-*p*-phenylenediamine (3m)**

p-Phenylenediamine (**2m**, 54 mg, 0.5 mmol) was similarly treated with isothiocyanate (**1A**, 261 mg, 1 mmol) and worked up as described for the preparation of **3l** to give **3m**.

Colorless needles, mp 287-290 °C (from DMF-H₂O). IR (KBr, tab.): 3430 (NH) cm⁻¹. ¹H NMR (500 MHz, DMSO-*d*₆) δ = 7.15 (2H, dd, J = 7.7, 7.6 Hz), 7.33 (2H, dd, J = 7.8, 7.4 Hz), 7.60 (2H, d, J = 8.0 Hz), 7.75-7.85 (6H, m), 10.45 (2H, s, NH x 2). ¹³C NMR (125 MHz, DMSO-*d*₆) δ = 118.7 (d), 118.9 (d), 120.9 (d), 122.0 (d), 125.7 (d), 129.9 (s), 135.3 (s), 152.1 (s), 161.7 (s). MS (EI): m/z (relative intensity, %) 374 (100, M⁺), 224 (8). HRMS (EI) m/z M⁺ calcd for C₂₀H₁₄N₄S₂: 374.0660, found: 374.0665.

Reaction of *o*-phenylenediamine (2n) with isothiocyanate (1A)

A mixture of isothiocyanate (**1A**, 261 mg, 1 mmol), *o*-phenylenediamine (**2n**, 54 mg, 0.5 mmol), Et₃N (0.14 mL, 10 mmol) and CuI (10 mg) in benzene (2.5 mL) was refluxed for 48 h. The obtained mixture was purified by silica gel chromatography using CHCl₃-MeOH (100:3) as eluent to give pure 2-aminobenzothiazole (**3n**), **5** and **6**.

***N,N'*-Bis(benzo[*d*]thiazol-2-yl)-*o*-phenylenediamine (3n)**

Colorless needles, mp 296-300 °C (from CHCl₃-hexane). IR (KBr, tab.): 3379 (NH) cm⁻¹. ¹H NMR (500 MHz, CDCl₃) δ = 7.00 (2H, ddd, J = 8.0, 7.8, 1.1 Hz), 7.20 (2H, ddd, J = 8.0, 7.3, 1.2 Hz), 7.31 (2H, dd, J

= 6.0, 3.5 Hz), 7.34 (2H, d, $J = 7.8$ Hz), 7.38 (2H, d, $J = 8.0$ Hz), 7.84 (2H, dd, $J = 6.0, 3.5$ Hz), 8.85-10.00 (2H, br, NH). ^{13}C NMR (125 MHz, CDCl_3) δ 118.9 (d), 120.7 (d), 122.2 (d), 124.6 (d), 126.0 (d), 126.7 (d), 129.9 (s), 133.9 (s), 150.8 (s), 166.1 (s). MS (EI): m/z (relative intensity, %) 374 (100, M^+), 341 (33), 239 (29), 225 (39). HRMS (EI) m/z M^+ calcd for $\text{C}_{20}\text{H}_{14}\text{N}_4\text{S}_2$: 374.0660, found: 374.0655.

2-[(2-Aminophenyl)amino]benzo[*d*]thiazole (5)

Colorless pinky prisms, 165-167 °C (from CHCl_3 -hexane). IR (KBr, tab.): 3444, 3425, 3377, 3340 (NH) cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ = 3.90-4.15 (2H, brs, NH_2), 6.81-6.89 (2H, m), 7.07 (1H, ddd, $J = 7.8, 7.7, 1.0$ Hz), 7.18 (1H, ddd, $J = 8.0, 7.9, 1.4$ Hz), 7.24 (1H, ddd, $J = 7.9, 7.5, 1.3$ Hz), 7.36-7.44 (2H, m), 7.52 (1H, dd, $J = 7.8, 0.7$ Hz), 9.25-9.65 (1H, brs, NH). ^{13}C NMR (125 MHz, CDCl_3) δ 116.6 (d), 118.7 (d), 119.2 (d), 120.9 (d), 121.9 (s), 125.7 (s), 126.0 (d), 127.6 (d), 128.7 (d), 130.3 (s), 142.9 (s), 151.7 (s), 169.3 (s). MS (EI): m/z (relative intensity, %) 241(100, M^+), 225 (45), 208 (88). HRMS (EI) m/z M^+ calcd for $\text{C}_{13}\text{H}_{11}\text{N}_3\text{S}$: 241.0674, found: 241.0677.

{2-[(2-Iodophenyl)amino]benz[*d*]imidazol-1-yl}benzo[*d*]thiazole (6)

Colorless prisms, 196-198 °C (from CHCl_3 -hexane). IR (KBr, tab.): 3442 (NH) cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ = 6.81 (1H, ddd, $J = 7.7, 7.5, 1.3$ Hz), 7.24 (1H, ddd, $J = 8.0, 7.6, 0.8$ Hz), 7.32 (1H, dd, $J = 7.4, 7.4$ Hz), 7.40 (1H, ddd, $J = 8.0, 7.3, 0.7$ Hz), 7.45 (1H, ddd, $J = 8.5, 7.1, 1.4$ Hz), 7.53 (1H, ddd, $J = 8.1, 7.3, 0.8$ Hz), 7.62 (1H, d, $J = 7.8$ Hz), 7.81-7.92 (3H, m), 8.08 (1H, d, $J = 8.1$ Hz), 8.84 (1H, dd, $J = 8.3, 1.4$ Hz), 11.25 (1H, s, NH). ^{13}C NMR (125 MHz, CDCl_3) δ 88.3 (s), 110.3 (d), 118.2 (d), 118.2 (d), 120.6 (d), 121.3 (d), 122.1 (d), 124.3 (d), 124.4 (d), 125.2 (d), 127.1 (d), 129.2 (d), 130.3 (s), 130.9 (s), 139.3 (d), 140.6 (s), 142.6 (s), 148.5 (s), 149.2 (s), 157.2 (s). MS (EI): m/z (relative intensity, %) 468 (81, M^+), 341 (100). HRMS (EI) m/z M^+ calcd for $\text{C}_{20}\text{H}_{13}\text{N}_4\text{SI}$: 467.9906, found: 467.9903.

N-(2-Iodophenyl)piperidine-1-carbothioamide (4Aa)

Piperidine (**2a**, 179 mg, 2.1 mmol) was added to a stirred solution of 2-iodophenyl isothiocyanate (**1A**, 522 mg, 2.0 mmol) in benzene (5 mL) at room temperature. The mixture was stirred for 5 min, and evaporated *in vacuo*. The obtained residual solid was recrystallized from benzene-hexane to give pure adduct **4Aa**. Yied: 657 mg (95%). Colorless prisms, mp 109-110.5 °C. IR (KBr-tab): cm^{-1} . ^1H NMR (500 MHz, CDCl_3) δ = 1.70, 3.84 (6H, br s, 4H, br s, $\text{CH}_2 \times 5$), 6.89, 7.33, 7.51, 7.81 (1H, ddd, $J = 8.0, 7.4, 1.6$ Hz), 1H, ddd, $J = 8.1, 7.4, 1.4$ Hz, 1H, dd, $J = 8.1, 1.6$ Hz, 1H, dd, $J = 8.0, 1.4$ Hz), 7.03 (1H, br, NH). ^{13}C NMR (125 MHz, CDCl_3) δ : 24.2 (t), 25.6 (t), 50.6 (t), 94.5 (s), 125.6 (d), 126.8 (d), 128.7 (d), 139.0 (d), 141.2 (s) 181.6 (s). MS (FAB): m/z (relative intensity, %) 347 (100, M^+), 219 (94), 128 (30), 84 (20). HRMS (FAB): m/z M^+ calcd for $\text{C}_{12}\text{H}_{16}\text{N}_2\text{IS}$: 347.0079; found: 347.0072.

Treatment of 4Aa with CuI and piperidine

Piperidine (**2a**, 213 mg, 2.5 mmol) and CuI (20 mg, 0.1 mmol) were added to a stirred solution of **4Aa** (347 mg, 1 mmol) in benzene (2.5 mL) at room temperature. The mixture was stirred for 5 min, and evaporated *in vacuo*. The obtained residual solid was recrystallized from benzene-hexane to give pure adduct **3a**. Yield: 213 mg (98%).

ACKNOWLEDGEMENTS

This work was supported in part by a Grant-in Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan. Thanks are due to Mr. Takahiro Teramae (Hokuriku University) for his technical assistance.

REFERENCES AND NOTES

1. Studies on Chalcogen-Containing Heterocycles. Part 35, For Part 34: M. Kaname and H. Sashida, *Tetrahedron Lett.*, 2011, **52**, 3279.
2. (a) S. L. Khokra, K. Arora, H. Mehta, A. Aggarwal, and M. Yadav, *International Journal Pharmaceutical Sciences and Research*, 2011, **2**, 1356; (b) J. K. Malik, F. V. Manvi, B. K. Nanjwade, S. Singh, and P. Purohit, *Der Pharmacia Letter*, 2010, **2**, 347; (c) L. Racané, H. Čičak, Z. Mihalić, G. Karminski-Zamola, and V. Tralić-Kulenović, *Tetrahedron*, 2011, **67**, 2760.
3. (a) A. Naya, K. Kobayashi, M. Ishikawa, K. Ohwaki, T. Saeki, K. Noguchi, and N. Ohtake, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 1219; (b) M. N. Greco, W. E. Hageman, E. T. Powell, J. J. Tighe, and F. J. Persico, *J. Med. Chem.*, 1992, **35**, 3180; (c) A. N. Choudhary, A. Kumar, and V. Juar, *Mini-Rev. Med. Chem.*, 2010, **10**, 705; (d) S. Massari, D. Daelemans, M. L. Barreca, A. Knezevich, S. Sabatini, V. Cecchetti, A. Marcello, C. Pannecouque, and O. Tabarrini, *J. Med. Chem.*, 2010, **53**, 641; (e) R. A. Glennon, J. J. Gaines, and M. E. Rogers, *J. Med. Chem.*, 1981, **24**, 766; (f) M. S. Gomaa, J. L. Armstrong, B. Bobillon, G. J. Veal, A. Brancale, C. P. F. Redfern, and C. Simons, *Bioorg. Med. Chem.*, 2008, **16**, 8301; (g) J. Van Heusden, R. Van Gineckel, H. Bruwiere, P. Moalans, B. Janssen, W. Floren, B. J. van der Leede, G. Sanz, M. Venet, L. Dillen, C. Van Hove, G. Willemsens, M. Janicot, and W. Wouters, *Br. J. Cancer*, 2002, **86**, 605; (h) M. S. Gomaa, J. L. Armstrong, B. Bobillon, G. J. Veal, A. Brancale, C. P. F. Redfern, and C. Simons, *Bioorg. Med. Chem.*, 2008, **16**, 8301; (i) C. Liu, J. Lin, S. Pitt, R. F. Zhang, J. S. Sack, S. E. Kiefer, K. Kish, A. M. Doweiko, H. Zhang, P. H. Marahe, J. Trzaskos, M. Mckinnon, J. H. Dodd, J. C. Barrish, G. L. Schieven, and K. Letheris, *Bioorg. Med. Chem.*, 2008, **16**, 1874; (j) E. Song, N. Kaur, N. Y. Park, Y. Jin, K. Lee, G. Kim, K. Y. Lee, J. S. Yang, J. H. Shin, K. Y. Nam, K. T. No, and G. Han, *Eur. J. Med. Chem.*, 2008, **43**, 1519; (k) P. L. Sangwan, J. L. Koul, S. Koul, M. V. Reddy, N. Thota, J. A. Khan, A. Kumar, N. P. Kallia, and G. N. Qazi, *Bioorg. Med. Chem.*, 2008, **16**, 9847.

4. Eq. 1: (a) A. K. Chakraborti, S. Rudrawar, G. Kaur, and L. Sharma, *Synlett*, 2004, 1533; (b) M. Kodomari, Y. Tamaru, and T. Aoyama, *Synth. Commun.*, 2004, **34**, 3029; (c) J. F. Mike, J. J. Inteman, A. Ellern, and M. Jeffries-EL, *J. Org. Chem.*, 2010, **75**, 495; (d) C. Zhu and T. Akiyama, *Synlett*, 2010, 2457; (e) D. Azarifar, K. Khosravi, Z. Najminejad, and K. Soleimani, *Heterocycles*, 2010, **81**, 2855; (f) X. Fan, Y. He, Y. Wang, Z. Xue, X. Zhang, and J. Wang, *Tetrahedron Lett.*, 2011, **52**, 899; (g) Y. Riadi, R. Mamouni, R. Azzalou, M. El Haddad, S. Roitier, G. Guillaumet, and S. Lazar, *Tetrahedron Lett.*, 2011, **52**, 3492.
5. Eq. 2: J. Hyvl and J. Srogl, *Eur. J. Org. Chem.*, 2010, 2849.
6. Eq. 3: (a) Q. Ding, X. He, and J. Wu, *J. Comb. Chem.*, 2009, **11**, 587; (b) Y.-J. Guo, R.-Y. Tang, P. Zhong, and J.-H. Li, *Tetrahedron Lett.*, 2010, **51**, 649; (c) W. Wang, W. Zhong, R. Zhou, J. Yu, J. Dai, Q. Ding, and Y. Peng, *Heterocycles*, 2010, **81**, 2841.
7. Eq. 4: (a) C. Bendí, F. Bravo, P. Uriz, E. Fernández, C. Claver, and S. Castellón, *Tetrahedron Lett.*, 2003, **44**, 6073; (b) L. L. Joyce, G. Evindar, and R. A. Batey, *Chem. Commun.*, 2004, 446; (c) G. Evindar and R. Batey, *J. Org. Chem.*, 2006, **71**, 1802; (d) J. Wang, F. Peng, J. Jiang, Z. Lu, L. Wang, J. Bai, and Y. Pan, *Tetrahedron Lett.*, 2008, **49**, 467; (e) E. A. Jaseer, D. J. C. Prasad, A. Dandapat, and G. Sekar, *Tetrahedron Lett.*, 2010, **51**, 5009; (f) E. Feng, H. Huang, Y. Zhou, D. Ye, H. Jiang, and H. Liu, *J. Comb. Chem.*, 2010, **12**, 422; (g) D. Ma, X. Lu, L. Shi, H. Zhang, Y. Jiang, and X. Liu, *Angew. Chem. Int. Ed.*, 2011, **50**, 1118.
8. Eq. 5: S. Murru, P. Mondal, R. Yella, and B. Patel, *Eur. J. Org. Chem.*, 2009, 5406.
9. Eq. 6: C. Li, X. Zhang, R. Tang, P. Zhong, and J. Li, *J. Org. Chem.*, 2010, **75**, 7037.
10. Eq. 7: J. Zhu, Z. Chen, H. Xie, S. Li, and Y. Wu, *Org. Lett.*, 2010, **12**, 2434.
11. Eq. 8: (a) D. S. Bose and M. Idrees, *J. Org. Chem.*, 2006, **71**, 8261; (b) N. K. Downer-Riley and Y. A. Jackson, *Tetrahedron*, 2008, **64**, 7741; (c) R. Yella, S. Murru, A. R. Ali, and B. Patel, *Org. Bio. Chem.*, 2010, **8**, 3389; (d) W. Lo, W. Hu, H. Lo, C. Chen, C. Kao, J. K. Vandavasi, and J. Wang, *Org. Lett.*, 2010, **12**, 5570.
12. Reviews: (a) H. Sashida, *Rev. Heteroatom Chem.*, 2000, **22**, 59; (b) H. Sashida, *J. Syn. Org. Chem. Jpn.*, 2001, **59**, 355; (c) H. Sashida, *Mini-Rev. in Org. Chem.*, 2007, **4**, 105; (d) H. Sashida and M. Minoura, *J. Syn. Org. Chem. Jpn.*, 2009, **67**, 714; (e) H. Sashida, *Heterocycles*, 2011, **83**, in press: DOI: 10.3987/REV-11-709.
13. Recent works: (a) H. Sashida, A. Nakayama, and M. Kaname, *Synthesis*, 2008, 3229; (b) H. Sashida, S. Nakabayashi, M. Kaname, and M. Minoura, *Heterocycles*, 2010, **80**, 1339; (c) H. Sashida, H. Satoh, K. Ohyanagi, and M. Kaname, *Molecules*, 2010, **15**, 1466; (d) H. Sashida, M. Kaname, and K. Ohyanagi, *Heterocycles*, 2010, **82**, 441; (e) H. Sashida, M. Kaname, A. Nakayama, H. Suzuki, and M. Minoura, *Tetrahedron*, 2010, **66**, 5149; (f) H. Sashida, S. Nakabayashi, H. Suzuki, M.

- Kaname, and M. Minoura, *Tetrahedron Lett.*, 2010, **51**, 5395; (g) M. Kaname, M. Minoura, and H. Sashida, *Tetrahedron Lett.*, 2011, **52**, 505.
14. Y. Xie, F. Zhang, J. Li, and X. Shi, *Synlett*, 2010, 901.
 15. M. D. Charles, P. Schults, and S. Buchward, *Org. Lett.*, 2005, **7**, 3965.
 16. L. L. Joyce and R. A. Batey, *Org. Lett.*, 2009, **11**, 2792.
 17. P. Saha, T. Ramana, N. Purkait, M.-A. Ali, R. Paul, and T. Punniyamurthy, *J. Org. Chem.*, 2009, **74**, 8719.
 18. R. Cano, D. J. Ramón, and M. Yus, *J. Org. Chem.*, 2011, **76**, 654.
 19. G. Shen, X. Lv, and W. Bao, *Eur. J. Org. Chem.*, 2009, 5897.
 20. (a) M. W. Hooper, M. Utsunomiya, and J. F. Hartwig, *J. Am. Chem. Soc.*, 1959, **81**, 5957; (b) J. J. D'Amico, C. C. Tung, and L. A. Walker, *J. Org. Chem.*, 2003, **68**, 2861.